Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Marchetti

Showing results (111-120 of 187) with videos related to

Pageof 19
Sort By:
Scientific Reports|May 6, 2021
Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary lossCristina Mussini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
The Journal of Infectious Diseases|August 27, 2002
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairmentGiulia Marchetti, Luca Meroni, Stefania Varchetta, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 26, 2026
Pre-ART platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio and the risk of non-AIDS-events, AIDS-events and mortality in people with HIVPaola Saltini, Alessandro Cozzi-Lepri, Giorgio Bozzi, et al.
AIDS Patient Care and Stds|December 7, 2017
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with DiscontinuationAntonio Di Biagio, Patrizia Lorenzini, Giulia Gustinetti, et al.
Journal of Clinical Microbiology|December 21, 2007
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesisAndrea Gori, Camilla Tincati, Giuliano Rizzardini, et al.
Journal of the International AIDS Society|November 15, 2014
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in ItalyAlessandro Cozzi-Lepri, Sergio Lo Caputo, Franco Maggiolo, et al.
Viruses|August 10, 2021
Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort StudyMartina Spaziante, Gloria Taliani, Giulia Marchetti, et al.
Journal of the International AIDS Society|November 14, 2014
CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in ItalyGiordano Madeddu, Antonella D'Arminio Monforte, Enrico Girardi, et al.
Journal of Medical Virology|September 27, 2023
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trialElena Bruzzesi, Arianna Gabrieli, Davide Bernasconi, et al.
Pageof 19

Showing results (111-120 of 187) with videos related to

Sort By:
Pageof 19
Scientific Reports|May 6, 2021
Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary lossCristina Mussini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, et al.
The Journal of Infectious Diseases|August 27, 2002
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairmentGiulia Marchetti, Luca Meroni, Stefania Varchetta, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 26, 2026
Pre-ART platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio and the risk of non-AIDS-events, AIDS-events and mortality in people with HIVPaola Saltini, Alessandro Cozzi-Lepri, Giorgio Bozzi, et al.
AIDS Patient Care and Stds|December 7, 2017
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with DiscontinuationAntonio Di Biagio, Patrizia Lorenzini, Giulia Gustinetti, et al.
Journal of Clinical Microbiology|December 21, 2007
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesisAndrea Gori, Camilla Tincati, Giuliano Rizzardini, et al.
Journal of the International AIDS Society|November 15, 2014
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in ItalyAlessandro Cozzi-Lepri, Sergio Lo Caputo, Franco Maggiolo, et al.
Viruses|August 10, 2021
Impact of HCV Eradication on Lipid Metabolism in HIV/HCV Coinfected Patients: Data from ICONA and HepaICONA Foundation Cohort StudyMartina Spaziante, Gloria Taliani, Giulia Marchetti, et al.
Journal of the International AIDS Society|November 14, 2014
CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in ItalyGiordano Madeddu, Antonella D'Arminio Monforte, Enrico Girardi, et al.
Journal of Medical Virology|September 27, 2023
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trialElena Bruzzesi, Arianna Gabrieli, Davide Bernasconi, et al.
Pageof 19